Retatrutide is an experimental medication currently being studied for the treatment of obesity, type 2 diabetes, and related metabolic conditions. It’s a triple hormone receptor agonist, meaning it targets GLP-1, GIP, and glucagon receptors—three key pathways involved in regulating appetite, blood sugar, and energy use.

Early clinical trials have shown that retatrutide may lead to significant weight loss, even greater than what’s been seen with medications like semaglutide or tirzepatide. It’s still in the clinical trial phase and not yet approved for general use.

If approved, it could become one of the most powerful treatments for obesity and metabolic diseases.